Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

Kessler Foundation50 enrolled

Overview

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Aphasia Stroke

Interventions

Wait first, then levetiracetamDRUG

Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.

Levetiracetam first, then waitDRUG

subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stroke * Aphasia * Can give consent Exclusion Criteria: * Renal failure * Pregnancy * Other neurological condition

Locations (1)

Kessler Foundation

West Orange, New Jersey, United States

Outcomes

Primary Outcomes

Speech and language assessment

Time frame: 6 months - 1year

Secondary Outcomes

Memory assessment

Time frame: 6 months to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.